About The Study: In this study, semaglutide for the secondary prevention of cardiovascular disease was effective but meeting conventional cost-effectiveness thresholds will require additional price reductions.
Corresponding Author: To contact the corresponding author, Dhruv S. Kazi, MD, MSc, MS, email dkazi@bidmc.harvard.edu .
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamacardio.2025.5243)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflicts of interest and financial disclosures, and funding and support.
# # #
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamacardiology/fullarticle/10.1001/jamacardio.2025.5243?guestAccessKey=72337825-a2fc-4d6b-8a11-b3df4c6edb95&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=020426
JAMA Cardiology